Showing results (1-10 of 588) with videos related to
Sort By:
Pageof 59
Annals of Internal Medicine|November 4, 2024
In adults with BMI ≥27 kg/m<sup>2</sup> and CVD, but without diabetes, semaglutide reduced MACE, regardless of baseline HbA<sub>1c</sub> levelDoreen Zhu, William G HerringtonAnnals of Internal Medicine|August 18, 2020
In patients with coronary disease and CKD, initial invasive therapy did not improve angina-related health statusWilliam G Herrington, Natalie StaplinAnnals of Internal Medicine|August 18, 2020
In patients with coronary disease and CKD, adding an invasive strategy to MT did not improve outcomesWilliam G Herrington, Natalie StaplinAnnals of Internal Medicine|November 4, 2024
In HF, T2D, CKD, or atherosclerotic CVD, SGLT2 inhibitors reduce HF hospitalizations and CV mortalityDoreen Zhu, William G HerringtonAnnals of Internal Medicine|December 1, 2025
In CKD, electronic letter nudges for patients or providers did not increase RASi or SGLT2i prescriptions at 6 moIain Turnbull, William G Herrington, Annals of Internal Medicine|May 2, 2022
In CKD, the Kidney Failure Risk Equation predicted 2-y risk for ESKD better than eGFR aloneDiego Aguilar-Ramirez, William G HerringtonNephron. Clinical Practice|February 18, 2011
Metformin: the safest hypoglycaemic agent in chronic kidney disease?Helen J Nye, William G HerringtonAnnals of Internal Medicine|May 2, 2022
In patients with type 2 diabetes and CKD, finerenone improved CV and kidney outcomesKaitlin J Mayne, William G HerringtonBritish Journal of Hospital Medicine (London, England : 2005)|January 19, 2010
Slowing the progression of chronic kidney diseaseWilliam G Herrington, Phil D MasonNature Reviews. Nephrology|November 2, 2019
Kidney disease trials for the 21st century: innovations in design and conductWilliam G Herrington, Natalie Staplin, Richard HaynesPageof 59